Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on integrin biology breakthroughs from the lab of noted entrepreneur and scientific founder Tim Springer, Morphic has developed an exclusive platform to build on these discoveries, complemented by a partnership with computational chemistry leader Schrödinger, Inc., that facilitates the rapid and iterative design of clinical candidates. Morphic was created in 2015 with support from Timothy Springer, PhD, Polaris Partners, Schrödinger Inc., and ShangPharma and raised $51.5M in 2016 from top tier investors. In September 2018, Morphic Therapeutic completed an $80 million Series B financing round to advance multiple programs into the clinic. We recently announced a collaboration with AbbVie on a subset of our fibrosis programs. Under the terms of the agreement, AbbVie paid Morphic an upfront payment of $100 million for exclusive license options on product candidates directed at multiple targets. Morphic retains co-development rights in liver indications. Integrins are involved in multiple disease areas, including inflammation, fibrosis, vascular diseases and cancer, and inhibitors are clinically validated. The combination of Morphic’s deep integrin expertise with your skills will enable a rapid path to novel and effective drugs for both orphan and blockbuster indications. Morphic’s laboratories are located in the AstraZeneca BioHub in Waltham, MA. We are looking for a scientist that displays integrity and pride in their work. An ideal candidate will be determined, value teamwork, and share Morphic’s compassion towards patients.
Morphic Therapeutic is seeking a highly motivated DMPK scientist (Sr. Scientist to Principle Scientist depending on qualification). The successful candidate will serve as the DMPK expert on project teams to evaluate underlying ADME mechanisms driving PK properties and to enable small molecule candidate optimization and prediction of clinical dosing regimens. The position will be part of a multi-disciplinary team at Morphic, working together towards transformative small molecule therapeutics for autoimmune and fibrotic diseases. A strong knowledge in drug transporter sciences and enzymology is required.
Design and supervise CROs for routine and mechanistic PK and ADME studies that enable compound optimization and decision making
Integrate PK and PKPD information and provide guidance to internal and external collaborators on the design and data interpretation for PK and PKPD studies
Partner closely with chemistry and biology colleagues to build compound screen and optimization strategies through mechanistic and quantitative understanding of PK and PD properties of drug candidates
Interface with development colleagues and lead the preparation of PK, ADME, and drug interaction data package for regulatory filings
Ph.D. in Drug Metabolism, Pharmacokinetics, Pharmaceutics or other relevant fields with >5 years of experience in the biopharmaceutical industry
Strong knowledge of drug transporters, ADME concepts, and bioanalytical principles is required
Experience in human PK prediction methodologies including allometry, IVIVC or PBPK
Experience in regulatory filing, in vitro and in vivo ADME assays and managing/collaborating with CROs
Strong organization, multi-tasking, interpersonal and communication skills
About Morphic Therapeutic
Morphic Therapeutic is leading the development of a new generation of oral integrin drugs.